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INTRODUCTION
Chemotherapy plays an important role in
the treatment of gynecologic malignancies and
particularly ovarian cancer. Chemotherapy, in
ovarian carcinoma, is administered after surgi-
cal treatment. The standard operation is hys-
terectomy with bilateral salpingo-oophorecto-
my, omentectomy and multiple biopsy of peri-
toneum. If disseminate carcinoma is present,
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Summary
The aim of our study was to evaluate the possible prognostic and predictive
significance of the expression of P-glycoprotein, a transmembrane transport
protein related to multidrug resistance, in previously untreated patients with
FIGO stage III ovarian cancer; to compare the results of immunocytochemical
analysis of tissue sections of tumors to the in vitro chemosensitivity to cyto-
toxic drug of fresh samples of the same tumors; and to evaluate survival in
women who underwent the same surgical treatment and the same adjuvant
chemotherapy.
Key words: Ovarian carcinoma, chemotherapy, P-glycoprotein, ATP-tumor
chemosensitivity assay.
Abbreviations: ATP: adenosine triphosphate; ATP-TCA: Adenosine
Triphosphate-Tumor Chemosensitivity Assay; AUC: area under the curve; CI:
confidence interval; HE: hematoxylin-eosin; MDR: multidrug-resistant; PEC: cis-
platin, epirubicin, cyclophosphamide; PFS: progression free; OS: overall sur-
vival; SE: standard error; TDC: standard test drug concentration; TGI: tumor
cell growth inhibition.
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the surgeon should remove as much tumor as
possible. Cisplatin-based combination
chemotherapy regimens produce complete
remissions in 60-80% of patients with residual
tumor mass (FIGO Stage III and IV) 1. However,
a significant fraction (20-40%) of patients with
advanced ovarian cancer will not achieve a
complete response to therapy. Drug resistance
is a major obstacle to the successful treatment
of ovarian carcinoma, with the development of
acquired resistance limiting the effectiveness of
chemotherapy. The increase in acquired resis-
tance to individual antineoplastic drugs in ovari-
an carcinoma is associated with broad cross-
resistance to structurally different drugs. The
knowledge of mechanisms responsible for resis-
tance to individual antineoplastic drugs and the
identification of multidrug resistance pheno-
types, which frequently accompany primary
resistance, can help the management of ovari-
an carcinoma by making use of new therapeu-
tic strategies for a better employment of
chemotherapy 2. The P-glycoprotein-specific
(Pgp) multidrug-resistant (MDR1) is the protein
studied and described in a wide variety of ani-
mal and human cell lines 3,4,5,6,7. Cells with
MDR phenotype overexpress P-glycoprotein
owing to gene amplification and increased lev-
els of P-glycoprotein mRNA 8. P-glycoprotein,
which has a molecular weight of 170 kilodal-
tons, functions as a trans-membrane ATP-
dependent drug efflux pump in drug-resistant
tumor cells 4. Increased levels of P-glycoprotein
or its mRNA have been reported in a variety of
neoplasias including ovarian carcinoma 9,10.
Typically, normal epithelial ovarian cells have
undetectable or low amounts of P-glycoprotein
when studied with immunohistochemical tech-
niques 11. Chemotherapeutic treatment is
selected in accordance with histologic type of
neoplasm. It is well known that patients with
the same histologic tumor do not respond to
the same treatment in the same way. 
Under these circumstances there is the need
to develop accurate methods to screen antiblas-
tic cytotoxicity of tumor explants in vitro in
order to establish adequate chemotherapy for
the single patient. A number of tumor
chemosensitivity assays (TCAs) have been
developed with the aim of assessing in vitro
drug sensitivity of established tumor cell lines or
of human tumor explants 12,13,14,15,16. Those
based on the inhibition of cell colony formation
17,18 and radioactive nucleic acid precursor
incorporation 19 have been characterized by
good sensitivity and accuracy. However, techni-
cal problems such as feasibility, risks, and costs
associated with their use prevent their wide-
spread application for clinical purposes and
have driven investigators to develop new alter-
native TCAs to assess patient response to
chemotherapy. A TCA based on the measure-
ment of adenosine triphosphate (ATP) by biolu-
minescence (ATP-TCA) has been recently pro-
posed to evaluate drug sensitivity rapidly from
fresh tumor samples 20,21,22,23. ATP may repre-
sent an important biochemically-based parame-
ter of drug-induced cytotoxicity since its intra-
cellular concentration correlates with the bio-
mass of living cells 24 and it deteriorates imme-
diately after cell death 25. The ATP biolumines-
cence assay is extremely sensitive and allows
extensive assessment of drug sensitivity in very
limited numbers of cells 26,27. 
We hereby report the results of an immuno-
histochemical study in which we tested the con-
nections between the MDR phenotype in 22
ovarian carcinoma cases from previously
untreated patients and the sensitivity in vitro of
fresh tumor samples of the same tumors to cis-
platin/epirubicin/cyclophosphamide with the
clinical response to chemotherapy and survival
of the patients after 5 years.
PATIENTS AND METHODS
Patients and samples 
Twenty-five patients aged 28-74 (mean
53.96 yr) with ovarian carcinoma were selected
between January, 1990 to December, 1993.
All patients underwent surgical removal of
tumor masses, along with total abdominal hys-
terectomy, adnexectomy and radical omentec-
tomy. The ATP-TCA assay was performed
immediately following primary surgery, but the
test results were not known to the physicians at
the t ime of determining postoperative
chemotherapy and therefore did not influence
the choice of regimen. Tumors were surgically
staged according to the FIGO staging system of
ovarian cancer 28. Twenty-two cases were
FIGO stage III and three were stage I. We
restricted our analysis to women with stage III
ovarian carcinoma for homogeneity. Nineteen
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tumors were serous, two were undifferentiated
carcinoma, one was endometrioid. On the basis
of degree of histopathologic differentiation, the
22 carcinomas were classified into low grade of
differentiation (G 3) (14 cases) and medium
grade (G 2) (8 cases). Of the 22 patients, 10
had minimal residual disease (<2 cm) and 12
bulk residual disease (>2 cm) on completion of
init ial surgery prior to chemotherapy.
Clinicopathologic characteristics of the patient
population are summarized in Table 1. All
women received a modified PEC regimen (cis-
platin 80 mg/m2 and cyclophosphamide 800
mg/m2 alternating with cisplatin 80 mg/m2
and epirubicin 75 mg/m2 for 12 cycles) after
primary surgery. At the time of our study the
first-line chemotherapy was PEC or PAC: tax-
anes, that have been recently introduced in
chemotherapy protocols, were used as second-
line therapy in patients who were resistant or
refractory to platin. 
TABLE 1 - Clinicopathologic characteristics of 22
patients with Stage III ovarian cancer.
Age
< 50 years 7
> 50 years 15
Histologic type
Serous 19
Endometrioid 1
Undifferentiated 2
Grade of differentiation
G2 8
G3 14
Residual tumor
<2 cm 10 
>2 cm 12
Clinical response to chemotherapy
Progression (P) 2
Stationary response (SR) 2
Partial response (PR) 7
Complete response (CR) 11
Patients’ response to chemotherapy was
evaluated according to WHO criteria 29: com-
plete response (CR), partial response (PR), sta-
tionary response (SR), progression (P).
The average follow-up period for each
patient, if possible, was 5 years after surgery.
The follow-up included pelvic examination,
measurement of tumor markers (CA 125,
CEA, CA 19.9) and pelvic and abdominal ultra-
sonography (every 3 months for 2 years, after-
wards every 6 months), computed tomography
of pelvis and abdomen (once a year).
Immunohistochemistry
Specimens were fixed in 10% buffered neu-
tral formaldehyde solution, adequately sampled
and embedded in paraffin. Some sections were
stained with hematoxylin-eosin (HE) for the
morphological evaluation, whereas other sec-
tions were mounted on electrostatic slides and
used for the immunohistochemical study. The
primary antibodies used were monoclonal anti-
body specific against anti-MDR1 (clone MDR
88, dilution 1: 100; Bio Genex, San Ramon,
CA) for 1 h RT. Once sections destined for
immunohistochemistry had been air-dried
overnight at 37°C, they were deparaffinized
with xylene and dehydrated through graded
alcohol. The endogenous peroxidase activity
was blocked by immersing the specimens in a
solution of 0.5% H2O2. To recover antigenicity,
slides were placed in a citrate buffer (10 mM,
pH 6.0) and submitted to microwave antigen
enhancement (300 W for 40 min). The sec-
tions were allowed to cool down to room tem-
perature, washed with phosphate-buffered
saline solution (PBS, pH 7.4) and treated with
normal horse serum (Lab Vision Corporation,
Fremont, CA) to reduce non-specific antibody
binding. After washing in PBS, the sections
were incubated with biotinylated anti-mouse
IgG (Lab Vision) and then with streptavidin-
biotin-peroxidase complex reagent (Lab Vision).
Successively to extensive washing with PBS,
the slides were treated with 3,3’-diaminobenzi-
dine-hydrogen peroxide (BioGenex, San
Ramon, CA), as final marker, and counter-
stained lightly with Mayer’s hematoxylin.
Negative control experiments were performed
by replacing the primary antibodies with non-
immune mouse serum at an equivalent protein
concentration.
The positive result of immunohistochemistry
reaction of specific antibody against anti-MDR
was assessed with a semi-qualitative method.
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Adenosine Triphosphate-Tumor Chemo-
sensitivity Assay (ATP-TCA)
Chemosensitivity studies were performed
with surgical biopsy specimens transported in
Dulbecco’s Modified Eagle’s Medium (DMEM)
containing 300 U/ml penicillin, 300 µg/ml
streptomycin, and 100 µg/ml kanamycin.
Specimens were tested only after selection of
appropriate tissue for histological evaluation.
Solid tumors were minced into 0.5-2.0 mm3
fragments under sterile conditions after excising
excess fat and normal tissue. Fragments were
then dissociated into a cell suspension of single
cells and small aggregates by incubation with a
mixture of enzymes (Tumor Dissociation
Enzyme Reagent, DCS Innovative Diagnostik
Sisteme, Hamburg, Germany) for 2-4 hours at
37°C. Following dissociation, the cells were
washed and, if viability was less than 60%,
non-viable debris was removed by Ficoll-
Hypaque density gradient centrifugation
(Histopaque; Sigma). Cells were washed twice
and resuspended for assay in a proprietary
serum-free medium (Complete Assay Medium,
CAM; DCS Innovative Diagnostik Sisteme,
Hamburg, Germany) at 1.0 - 2.0 x105 cells/ml
as previously described 21. 
A total of 22 primary ovarian tumors were
assayed simultaneously with cisplatin, epirubicin
and cyclophosphamide as single agents and in
combination. Therapeutic grade drugs from
commercial sources were stored, prepared, and
used before expiration dates according to the
manufacturer. Single agents and drug combina-
tions were tested at six dilutions corresponding
to 200%, 100%, 50%, 25%, 12.5% and
6.25% of a standard test drug concentration
(TDC). TDC values were determined by phar-
macokinetic and clinical information. Standard
100% TDC values were 3.8 µg/ml for cis-
platin, and 0.5 µg/ml for epirubicin and 3
µg/ml for 4-hydroperoxy- cyclophosphamide
(cyclophosphamide in vitro active metabolite).
Drug combinations were tested by combining
single agents. Fresh drug solutions were used.
The ATP-TCA was performed according to the
manufacturer’s instructions and previously pub-
l ished methods 21. Cultures of 10,000 –
20,000 cells were tested in 96-well round-bot-
tom polypropylene microplates (Costar). Each
microplate was used to test four single agents
or drug combinations at six concentrations in
triplicate. Microplates contained 12 no-inhibi-
tion control cultures (Mo) and 12 maximum
inhibition control cultures (Mi). Controls were
set up by adding 0.1 ml of cell suspension to
0.1 ml of CAM (no inhibition control cultures,
Mo), or to 0.1 ml of maximum ATP inhibitor
(maximum inhibition control cultures, Mi). Test
drug di lut ions were set up in culture
microplates by doubling dilutions of fresh 400%
TDC solutions in 0.1 ml CAM/well before
adding 0.1 ml cell suspension/well. After incu-
bation of the cultures for 6 days at 37°C in a
98% humidified, 95% air-5%CO2 atmosphere,
cellular ATP was extracted and stabilized by
mixing 0.05 ml of Tumor Cell Extraction
Reagent (TCER) into each well. Cellular ATP
was then measured in a luminometer
(MicroLumat 952; Berthold, Wilbad, Germany)
using 0.05 ml of cellular extract injected with
0.1 ml of luciferin-luciferase reagent (DCS
Innovative Diagnostik Sisteme, Hamburg,
Germany). A count integration time of 10 sec-
onds with a 4-second delay was used.
Statistical analysis
The statistical analysis was performed using
Fisher’s exact test. Progression free survival
(PFS) and overall survival (OS) curves were con-
structed by Kaplan-Meier estimates.
RESULTS
Immunohistochemistry of P-glycoprotein in
ovarian carcinoma cells
Table 2 shows the results of immunocyto-
chemical study on 22 cases of ovarian carcino-
ma. In 16 cases (72.72%) the antibody investi-
gated (multi-drug resistance marker) shows dis-
t inct plasma membrane and cytoplasm
immunoreactivity in epithelial elements (Figure
1).
ATP-tumor chemosensitivity assay.
Analysis of results
Tumor cell growth inhibition (TGI) values for
each TDC were calculated according to the fol-
lowing equation:
(TDC) - (Mi)
TGI = 1.0 - ______________________ x 100
(Mo)-(Mi)
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FIGURE 1 - The antibody investigated (multi-drug resis-
tance marker) shows distinct plasma membrane and cyto-
plasm immunoreactivity in epithelial elements.
where Mo = means for no-inhibition control
cultures, Mi = means for maximum inhibition
control cultures, and TDC = means for repli-
cate test drug cultures. Area under the curve
(AUC) values of the percentage of TGI vs the
percentage of TDC were calculated by the
trapezoidal rule. IC50 values were determined
by plotting the percentage of tumor growth as
a function of drug concentrations. The degree
of sensitivity/resistance to anticancer drugs of
tumor samples was calculated according to
Andreotti et al. 20, based on the AUC values of
the entire concentration range tested (200-
6.25% TDC), %TGI at 200% TDC and IC50. In
particular we classified patients as resistant
(when the AUC value resulted <12500) and
sensit ive (when the AUC value resulted
TABLE 2 - Patient characteristics and their correlation with P-glycoprotein expression and ATP-tumor chemosensi-
tivity assay.
Case Age Histological Grade Residual MDR TCA Clinical Progression Overall 
(years) type tumor response to free survival
chemotherapy (months) (months)
1 42 Serous G2 < 2 cm NEG R CR 35 60
2 52 Serous G3 > 2 cm NEG S CR 8 28 
3 59 Serous G3 < 2 cm NEG S CR 37 60
4 74 Serous G3 > 2 cm POS R P 0 10
5 60 Serous G2 < 2 cm POS R CR 6 15
6 28 Serous G2 > 2 cm POS R CR 7 15
7 47 Serous G2 < 2 cm POS R CR 18 35
8 68 Serous G3 < 2 cm NEG S CR 60 60
9 33 Serous G2 > 2 cm POS R P 2 33
10 43 undifferentiated G3 > 2 cm POS R SR 5 12
11 69 serous G3 > 2 cm POS R CR 4 28
12 63 serous G3 < 2 cm NEG S CR 60 60
13 50 serous G2 < 2 cm POS S CR 22 48
14 42 endometrioid G3 > 2 cm POS R PR 4 17
15 65 serous G3 > 2 cm POS R SR 10 21
16 61 serous G3 < 2 cm NEG S CR 37 60
17 54 serous G3 > 2 cm POS R PR 6 25
18 67 serous G2 > 2 cm POS R PR 6 35
19 52 serous G2 < 2 cm POS R PR 16 33
20 54 undifferentiated G3 < 2 cm POS R PR 16 28
21 58 serous G3 > 2 cm POS R PR 12 37
22 52 serous G3 > 2 cm POS R PR 14 26
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>12500). Tumors were considered to be
chemosensitive if they demonstrated in vitro
chemosensitivity to the combination used clini-
cally. In 16 cases we proved chemoresistance,
in 6 cases we proved chemosensitivity.
Relation to clinicopathological variables
Clinical and histopathologic variables and
their correlations with P-glycoprotein expres-
sion and ATP-TCA results are shown in Table
2. A statistically significant negative correlation
was found between MDR-phenotype both with
the clinical response to chemotherapy (p =
0.012) and with the survival of the patients
after 5 years (p = 0.0001). All 16 patients with
P-glycoprotein expression in ovarian carcinoma
cells had died within 5 years after surgery; on
the other hand, 6 patients out of 6 MDR-nega-
tive cases showed a complete clinical response
to chemotherapy and 5 of them were alive,
with no evident disease, after 5 years. Of the
12 patients with bulk residual disease (>2 cm),
11 were MDR positive and only one was MDR
negative; also in 11 cases we found chemore-
sistance of primary cell lines cultured in vitro
and only in one case did we find chemosensi-
tive cells. These two data are highly significant
(p <0.0001). Moreover, of the 12 patients with
bulk residual disease, only 3 had a CR to
chemotherapy (p = 0.03). In addition the
chemoresistance/ chemosensitivity of primary
cell lines cultured in vitro was statistically signif-
icantly correlated both with the cl inical
response to chemotherapy (p=0.012) and with
patient’s survival after 5 years (p = 0.009). All
6 patients defined as sensitive by the ATP-TCA
showed a complete response to chemotherapy;
whereas 5 of the 16 in vitro resistant patients
had a CR to therapy, but only one was alive
with no evident disease after 5 years. Fifteen
out of 16 patients who were resistant on the
basis of ATP-TCA died within 5 years after
surgery. 
The results of the immunocytochemical
study compared with the results of tumor
chemosensitivity assay are shown in Table 3. A
statistically significant positive correlation (p =
0.001) was found when comparing the results
of the two techniques; out of 16 MDR-positive
cases, 15 were chemoresistant as detected by
the ATP-TCA while 5 of 6 MDR-negative cases
were defined as chemosensitive by the ATP-
TCA. 
TABLE 3 - A significant positive correlation between
the results of the two techniques compared.
MDR negative MDR positive Total
In vitro sensitivity 5 1 6
In vitro resistance 1 15 16
Total 6 16 22
In the present study we correlated the mul-
tidrug resistance phenotype and ATP-TCA
results with PFS and OS as shown in Figure 2.
The mean time predicted by MDR-negative for
PFS and OS was 44 (SE 9; 95% CI 25-62) and
64.67 (SE 6.69; 95% CI 51.55-77.79)
months, respectively. MDR-positive patients
had a significantly lower mean PFS and OS of
9 (SE 2; 95% CI 6-12) and 26.13 (SE 2.64;
95% CI 20.95-31.3) months, respectively. The
mean time predicted by in vitro sensitivity for
PFS and OS was 41 (SE 10; 95% CI 22-60)
and 60.67 (SE 6.95; 95% CI 47.4-74.3)
months, respectively. Patients predicted to be
resistant in vitro had a significantly lower mean
PFS and OS of 10 (SE 2; 95% C 6-14) and
27.63 (SE 3.57; 95% CI 20.63 -34.62)
months, respectively. 
DISCUSSION
Epithelial ovarian cancer is the leading
cause of cancer death due to gynecological
malignancies for women in Europe and the
United States 30. The high mortality resulting
from of ovarian cancer is due in part to its late
stage of presentation. In advanced epithelial
ovarian cancer, chemotherapy is administered
as adjuvant therapy fol lowing debulking
surgery. Improvements in cancer chemotherapy
have significantly improved patient survival over
the past two decades, however, the ultimate
success of treatment is limited by the occur-
rence of drug resistance in tumor cells 31 and
by residual tumor after surgery. Tumor cell
resistance to cytotoxic drugs is thought to be a
major cause of failure in the chemotherapy of
malignant tumors. In some tumors, resistance
to chemotherapy is already present at diagno-
sis. More commonly, resistance develops during
the course of treatment, probably resulting
from the selection and proliferation of subpop-
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ulations of drug-resistant cells. Tumors may
strongly vary in their responses to particular
cytotoxic drug. Most of the studies in the litera-
ture on P-glycoprotein expression in ovarian
cancer include only a small numbers of cases
and therefore they are difficult to interpret.
Sometimes the papers describe mixtures of pre-
and postchemotherapy tissue specimens, bor-
derline and non-epithelial tumors and some-
times specimens from patients with different
stage of the disease and thus with different
prognoses are analyzed. The difficulty in com-
paring the results in literature comes from the
various methodologies used: for example, fresh
versus formalin-fixed tissue, or use of different
monoclonal antibodies. From these considera-
tions it seems that an ideal method for all tis-
sues and tumor types for determining MDR-
1/P-glycoprotein does not exist. However the
immunohistochemical techniques seem to have
important advantages in the study of tissue
samples from solid tumors: the specimens
embedded in paraffin allow many histologic
sections and for better morphological analysis
compared with frozen sections. Our experimen-
tal data of immunocytochemical analysis of tis-
sue sections from 22 selected patients with
stage III ovarian cancer, show a negative corre-
lation between P-glycoprotein expression and
the survival of women with advanced ovarian
carcinoma and residual tumor after surgery.
The above results indicate the necessity of
investigating a larger series of patients, includ-
ing those treated with taxanes. The choice of
drug is not based on individualized in vitro sen-
sitivity, but on reported response rates of clini-
cal trials 32; nevertheless the tumor can change
the response to chemotherapy. 
The possibility of optimizing anticancer
chemotherapy is today provided when studying
the chemosensitivity or resistance of tumor
explants from cancer patients using innovative,
highly reliable, biochemical, molecular or
immunohistochemical methodologies, capable
of detecting the expression of gene products
responsible for the occurrence of these phe-
nomena 33,34 and by use of in vitro chemosen-
sitivity tests 12,13,14,16,35. In the near future, data
obtained from these methods may contribute to
the prediction of clinical response to specific
antineoplastic agents, and help guide the
choice of optimum pharmacological treatment
FIGURE 2 - Progression-
free and overall survival of
MDR-positive versus MDR-
negative patients (panels a and
b) and of in vitro sensitive ver-
sus resistant patients (panels c
and d).
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for individual patients. Our evaluation of the
sensitivity in vitro of fresh tumor samples to
the most commonly used drugs in ovarian car-
cinoma evidences the immunohistochemical
role in evaluating tumor cell response to
chemotherapy. These data also may contribute
to individualizing clinical trials of postoperative
chemotherapy.
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